The results revealed that EZH2 and HDAC1/2 were frequently upregulated in patients with PTCL, and patients with higher EZH2 and HDAC2 expression usually exhibited a poorer survival rate [21]. The gene discussed is HDAC2; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.